Miconazolnitraat Samenwerkende Apothekers may be available in the countries listed below.
Miconazole nitrate (a derivative of Miconazole) is reported as an ingredient of Miconazolnitraat Samenwerkende Apothekers in the following countries:
International Drug Name Search
Nitrendipin-1A Pharma may be available in the countries listed below.
Nitrendipine is reported as an ingredient of Nitrendipin-1A Pharma in the following countries:
International Drug Name Search
Cordran® (Flurandrenolide, USP) is a potent corticosteroid intended for topical use. Flurandrenolide occurs as white to off-white, fluffy, crystalline powder and is odorless. Flurandrenolide is practically insoluble in water and in ether. One g dissolves in 72 mL of alcohol and in 10 mL of chloroform. The molecular weight of flurandrenolide is 436.52.
The chemical name of flurandrenolide is Pregn-4-ene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis (oxy)]-, (6α, 11β, 16α)-; its empirical formula is C24H33FO6. The structure is as follows:
Flurandrenolide Chemical Structure
Each g of Cordran® SP Cream (Flurandrenolide Cream, USP) contains 0.5 mg (1.145 μmol; 0.05%) or 0.25 mg (0.57 μmol; 0.025%) flurandrenolide in an emulsified base composed of cetyl alcohol, citric acid, mineral oil, polyoxyl 40 stearate, propylene glycol, sodium citrate, stearic acid, and purified water.
Each g of Cordran® Ointment (Flurandrenolide Ointment, USP) contains 0.5 mg (1.145 μmol; 0.05%) or 0.25 mg (0.57 μmol; 0.025%) flurandrenolide in a base composed of white wax, cetyl alcohol, sorbitan sesquioleate, and white petrolatum.
Cordran is primarily effective because of its anti-inflammatory, antipruritic, and vasoconstrictive actions.
The mechanism of the anti-inflammatory effect of topical corticosteroids is not completely understood. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Corticosteroids with anti-inflammatory activity may stabilize cellular and lysosomal membranes. There is also the suggestion that the effect on the membranes of lysosomes prevents the release of proteolytic enzymes and, thus, plays a part in reducing inflammation.
Pharmacokinetics—The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.
Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see DOSAGE AND ADMINISTRATION).
Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. They are metabolized primarily in the liver and then excreted in the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Cordran is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Topical corticosteroids are contraindicated in patients with a history of hypersensitivity to any of the components of these preparations.
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.
Conditions that augment systemic absorption include application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.
Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression using urinary-free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.
Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, so that supplemental systemic corticosteroids are required.
Pediatric patients may absorb proportionately larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see Pediatric Use under PRECAUTIONS).
If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.
In the presence of dermatologic infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, Cordran should be discontinued until the infection has been adequately controlled.
Patients using topical corticosteroids should receive the following information and instructions:
This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
Patients should be advised not to use this medication for any disorder other than that for which it was prescribed.
The treated skin area should not be bandaged or otherwise covered or wrapped in order to be occlusive unless the patient is directed to do so by the physician.
Patients should report any signs of local adverse reactions, especially under occlusive dressing.
Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a patient being treated in the diaper area, because these garments may constitute occlusive dressings.
The following tests may be helpful in evaluating the HPA axis suppression:
Urinary-free cortisol test
ACTH stimulation test
Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.
Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.
Pregnancy Category C—Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively for pregnant patients or in large amounts or for prolonged periods of time.
It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.
Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than do mature patients because of a larger skin surface area to body weight ratio.
Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients.
The following local adverse reactions are reported infrequently with topical corticosteroids but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:
Burning
Itching
Irritation
Dryness
Folliculitis
Hypertrichosis
Acneform eruptions
Hypopigmentation
Perioral dermatitis
Allergic contact dermatitis
The following may occur more frequently with occlusive dressings:
Maceration of the skin
Secondary infection
Skin atrophy
Striae
Miliaria
Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).
Topical corticosteroids are generally applied to the affected area as a thin film 1 to 4 times daily, depending on the severity of the condition.
For moist lesions, a small quantity of the cream should be rubbed gently into the affected areas 2 or 3 times a day. For dry, scaly lesions, the ointment is applied as a thin film to affected areas 2 or 3 times daily.
Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions.
If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Use With Occlusive Dressings
The technique of occlusive dressings (for management of psoriasis and other persistent dermatoses) is as follows:
Remove as much as possible of the superficial scaling before applying Cordran SP Cream or Cordran Ointment. Soaking in a bath will help soften the scales and permit easier removal by brushing, picking, or rubbing.
Rub Cordran SP Cream or Cordran Ointment thoroughly into the affected areas.
Cover with an occlusive plastic film, such as polyethylene, Saran Wrap™, or Handi-Wrap®. (When Cordran SP Cream is used, added moisture may be provided by placing a slightly dampened cloth or gauze over the lesion before the plastic film is applied.)
Seal the edges to adjacent normal skin with tape or hold in place by a gauze wrapping.
For convenience, the patient may remove the dressing during the day. The dressing should then be reapplied each night.
For daytime therapy, the condition may be treated by rubbing Cordran SP Cream or Cordran Ointment sparingly into the affected areas.
In more resistant cases, leaving the dressing in place for 3 to 4 days at a time may result in a better response.
Thin polyethylene gloves are suitable for treatment of the hands and fingers; plastic garment bags may be utilized for treating lesions on the trunk or buttocks. A tight shower cap is useful in treating lesions on the scalp.
Occlusive Dressings Have the Following Advantages—
Percutaneous penetration of the corticosteroid is enhanced.
Medication is concentrated on the areas of skin where it is most needed.
This method of administration frequently is more effective in very resistant dermatoses than is the conventional application of Cordran.
Precautions to Be Observed in Therapy With Occlusive Dressings—Treatment should be continued for at least a few days after clearing of the lesions. If it is stopped too soon, a relapse may occur. Reinstitution of treatment frequently will cause remission.
Because of the increased hazard of secondary infection from resistant strains of staphylococci among hospitalized patients, it is suggested that the use of occlusive plastic films for corticosteroid therapy in such cases be restricted.
Generally, occlusive dressings should not be used on weeping, or exudative, lesions.
When large areas of the body are covered, thermal homeostasis may be impaired. If elevation of body temperature occurs, use of the occlusive dressing should be discontinued.
Rarely, a patient may develop miliaria, folliculitis, or a sensitivity to either the particular dressing material or a combination of Cordran and the occlusive dressing. If miliaria or folliculitis occurs, use of the occlusive dressing should be discontinued. Treatment by inunction with a corticosteroid such as Cordran may be continued. If the sensitivity is caused by the particular material of the dressing, substitution of a different material may be tried.
Warnings—Some plastic films are readily flammable. Patients should be cautioned against the use of any such material.
When plastic films are used on pediatric patients, the persons caring for the patients must be reminded of the danger of suffocation if the plastic material accidentally covers the face.
Cream:
0.025%, 30 g, NDC 16110-034-30; 60 g, NDC 16110-034-60
0.05%, 15 g, NDC 16110-035-15; 30 g, NDC 16110-035-30;
60 g, NDC 16110-035-60
Ointment:
0.025%, 30 g, NDC 16110-024-30; 60 g, NDC 16110-024-60
0.05%, 15 g, NDC 16110-026-15; 30 g, NDC 16110-026-30;
60 g, NDC 16110-026-60
Store at controlled room temperature, 59°-86°F (15°-30°C).
Rx only.
Literature revised February 2006
Marketed by:
Aqua Pharmaceuticals, LLC
Malvern, PA 19355
Under License from:
Oclassen Dermatologics
A Division of Watson Pharma, Inc.
Corona, CA 92880 USA
Manufactured by:
DPT Laboratories, Ltd.
San Antonio, TX 78215
PRINTED IN USA
128401
Cordran® SP 0.05%
Flurandrenolide Cream, USP
15 g Tube Carton
NDC 16110-035-15
Cordran® SP 0.05%
Flurandrenolide Cream, USP
30 g tube carton
NDC 16110-035-30
Cordran® SP 0.05%
Flurandrenolide Cream, USP
60 g tube carton
NDC 16110-035-60
| Cordran flurandrenolide cream | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA | NDA012806 | 10/18/1965 | |
| Cordran flurandrenolide cream | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA | NDA012806 | 10/18/1965 | |
| Cordran flurandrenolide ointment | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA | NDA012806 | 10/18/1965 | |
| Cordran flurandrenolide ointment | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA | NDA012806 | 10/18/1965 | |
| Labeler - Aqua Pharmaceuticals, LLC (300538265) |
Aptivus is used along with another HIV medicine (ritonavir). Serious and sometimes fatal bleeding in the brain has occurred with this combination. Contact your doctor immediately if you develop symptoms of bleeding in the brain. These may include confusion, vision or speech problems, or one-sided weakness.
Serious and sometimes fatal liver problems have also been reported with this combination. Patients who have hepatitis B or C may be at greater risk. Contact your doctor at once if you develop symptoms of liver problems. Such symptoms may include yellowing of the eyes or skin, dark urine, pale stools, stomach pain or tenderness, severe or persistent nausea, or loss of appetite.
Discuss any questions or concerns with your doctor.
Treating HIV infection. Aptivus should be used with ritonavir.
Aptivus is a protease inhibitor. It works by blocking the growth of an enzyme (HIV protease) that the HIV virus needs to reproduce in the body.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Aptivus. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Aptivus. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Aptivus may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Aptivus as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Aptivus.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Cough; diarrhea; headache; nausea; tiredness; vomiting.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); body fat changes; confusion; dark urine; depression; difficulty urinating; dizziness; excessive hunger, thirst, or urination; fast heartbeat; fever, chills, or sore throat; flu-like symptoms; fruit-like breath odor; itching; joint pain or stiffness; loss of appetite; mental or mood changes; mouth sores or ulcers; muscle pain; numbness or tingling; pale stools; red, blistered, swollen, or peeling skin; severe or persistent nausea; shortness of breath; slurred speech or one-sided weakness; stomach pain or tenderness; throat tightness; unusual bruising or bleeding; unusual drowsiness or tiredness; unusual weakness; vision changes; yellowing of the skin or eyes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Aptivus side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Before opening the bottle, store Aptivus in the refrigerator between 36 and 46 degrees F (2 and 8 degrees C). Do not freeze. After opening the bottle, store Aptivus at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Aptivus must be used within 60 days after opening the bottle. Keep the bottle tightly closed. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Aptivus out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Aptivus. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Famotidine 10 mg
Acid reducer
Allergy alert: Do not use if you are allergic to famotidine or other acid reducers
ask a health professional before use.
In case of overdose, get medical help or contact a Poison Control Center right away.
carnauba wax, hypromellose, iron oxides, magnesium stearate, microcrystalline cellulose, pregelatinized starch, polydextrose, polyethylene glycol, talc, titanium dioxide, triacetin
1-800-719-9260
Compare to Original Strength Pepcid® AC active ingredient
Original Strength
Acid Controller
Famotidine Tablets, 10 mg
Acid Reducer
Just One Tablet Prevents & Relieves Heartburn Due to Acid Indigestion
Actual Size
Tablets
Acid Controller Carton
| ACID CONTROLLER ORIGINAL STRENGTH famotidine tablet | ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| ANDA | ANDA075400 | 08/28/2009 | |
| Labeler - Walgreen Company (008965063) |
Amoxclav-Sandoz may be available in the countries listed below.
Amoxicillin sodium salt (a derivative of Amoxicillin) is reported as an ingredient of Amoxclav-Sandoz in the following countries:
Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Amoxclav-Sandoz in the following countries:
Clavulanic Acid potassium (a derivative of Clavulanic Acid) is reported as an ingredient of Amoxclav-Sandoz in the following countries:
International Drug Name Search
Fentikol may be available in the countries listed below.
Fenticonazole nitrate (a derivative of Fenticonazole) is reported as an ingredient of Fentikol in the following countries:
International Drug Name Search
